Drugs / recombinant humanized anti-CD25 monoclonal antibody
recombinant humanized anti-CD25 monoclonal antibody
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06657391 | Oct 2024 → Sep 2027 expected | inherited hemoglobinopathy | Rongrong Liu | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07029958 | Nov 2024 → Oct 2029 expected | Epstein-Barr virus-associated lymphoproliferative disorder | Beijing Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant humanized anti-CD25 monoclonal antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06657391 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-CD25 monoclonal antibody” NCT06657391 ↗ |